Prevent Diabetic Kidney Disease Among Egyptians

The National Plan To Prevent Diabetic Kidney Disease Among Egyptians: A Prospective Multicenter Randomized Controlled Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06071208

Enrollment

10000

Registered

2023-10-06

Start date

2023-10-14

Completion date

2028-12-14

Last updated

2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Without Complication

Brief summary

Study of the possibility to prevent the development of Diabetic kidney disease in type 2 diabetic patients

Detailed description

Study of the possible role of the SGLT2 inhibitors to prevent the development of frank type2 DM among prediabetic candidates. Study of the possible role of the SGLT2 inhibitors to prevent the development of diabetic complications, namely diabetic kidney disease, diabetic retinopathy and neuropathy.

Interventions

DRUGGliflozin

to study whether the use of gliflozin prevented diabetic complications

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* diabetics,prediabetics

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
prevention of diabetic complications	5 years	glomerular filtration rate will be measured at the beginning of the study and at the end

Contacts

Primary ContactAhmed Fayed, MD

dr.fayed@gmail.com+201142700904

Backup ContactMohammed Hegazy, MD

mohammed.hegazy@ngu.edu.eg/+201205408765

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026